 flow cytometri clinic estim hematopoiet progenitor autolog transplant cancer patient optimum method hematopoiet progenitor autolog transplant myeloabl cancer therapi uncertain lack assay marrow-repopul stem cell cfu-gm assay use indirect indic qualiti graft standard result evalu knowledg hematopoiet progenitor differenti antigen dual-color direct immunofluoresc flow cytometri aim cfu-gm assay purpos assay blood sampl differ recoveri pancytopenia high-dos cyclophosphamid etoposid cancer therapi recombin human GM colony-stimul factor rhgm-csf appear cell circul hematopoiet progenitor cfu-gm/ml level adequ large-scal harvest leukapheresi total cell cfu-gm data linear regress line equat cfu-gm/ml cell microlit seri patient myeloabl chemoradiotherapi earli hematopoiet recoveri marrow function number transplant cell total nucleat cell cfu-gm cell cell data articl favor clinic use flow cytometri harvest hematopoiet progenitor autolog transplant contribut understand role hematopoiet progenitor cell subset marrow recoveri myeloabl cancer therapi